Cullinan Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cullinan Therapeutics Inc 's ROA in the second quarter of 2026?
Cullinan Therapeutics Inc recorded a cumulative net loss of $-205 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -48.17%.

However, within the Healthcare sector 553 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3903, from total ROA ranking in the first quarter of 2026 at 4502.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-30.15 %	-30.49 %	-27.89 %	-25.74 %	-23.49 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-205	-221	-220	-217	-207
Return On Assets (TTM)	-48.17 %	-47.62 %	-43.25 %	-39.29 %	-34.82 %
CGEM's Total Ranking	# 3903	# 4502	# 3893	# 3870	# 3812
Total Assets (TTM) in million	364	403	448	485	521
Seq. Total Assets Change	-9.73 %	-10.12 %	-7.5 %	-6.92 %	-10.17 %
Seq. Net Income Change	-	-	-	-	-

CGEM's 5 Years Annual ROA >> Back to CGEM Management Effectiveness >> Compare CGEM ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 78
Sector	# 554
Overall	# 3872

Return On Assets Statistics
High	Average	Low
21.79 %	-348.87 %	-1615.18 %
(Jun 30 2022)		(Mar 31 2014)

Financial Statements
Cullinan Therapeutics Inc 's Assets	$ 364 million	CGEM's Balance sheet
Cullinan Therapeutics Inc 's Income	$ -54 million	Quarterly CGEM's Income Statement
CGEM's Income by Division		See CGEM's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-18.52 %	28.69 %	-13.49 %	27.76 %	12598891.35 %
Total Assets in million	507	622	483	559	437
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-220	-168	-155	109	-67
Annual Return On Assets	-43.4 %	-26.95 %	-32.1 %	19.55 %	-15.44 %

CGEM's 5 Years Annual ROA >> Back to CGEM Management Effectiveness >> Compare CGEM ROA to its Competitors

More Return On Assets Ratios
CGEM's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CGEM's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CGEM's Competitors
Subscribers only: Roa for Cullinan Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CGEM's Customers

You may also want to know
CGEM's Roi	CGEM's Inventory Turnover Ratio	CGEM's Growth Rates	CGEM's Dividend Comparisons
	CGEM's Profitability Ratios	CGEM's Asset Turnover Ratio	CGEM's Dividend Growth
CGEM's Roe	CGEM's Valuation Ratios	CGEM's Financial Strength Ratios	CGEM's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:39:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.